Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites

Inclusion Criteria: * Male or female participants ≥18 years of age. * Participants with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology). * Participants who have been hospitalized for acute decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring diuretic therapy) with or without ACLF at admission or during hospitalization but without ACLF at Screening. * In participants with cirrhosis due to hepatitis B virus, decompensation must occur in the setting of continuous (no less than 3 months) appropriate antiviral therapy. * In participants with cirrhosis due to hepatitis C virus, only decompensated participants who will not receive antiviral therapy during the study period will be included (Participants receiving antiviral therapy within 14 days prior to enrollment cannot be included in the study). * In participants with cirrhosis due to autoimmune hepatitis, decompensation must occur in the setting of continuous immunosuppressive therapy. * Participants must be willing and able to provide written informed consent or have an authorized representative able to provide written informed consent on behalf of the participant in accordance with local law and institutional policy. * Chronic liver failure-consortium acute decompensation (CLIF-C AD) score \> 50 points at screening. Exclusion Criteria: * Participants with ACLF at Screening * Participants with type 1 hepatorenal syndr…